Focus: Rhythm Pharmaceuticals is a public specialty pharma company focused on peptide therapeutics for rare genetic obesity and neurological indications. With 201-500 employees and $77M in FY2025 revenue, they operate as a focused, commercial-stage biotech.
Profile data last refreshed 55m ago · AI intelligence enriched 2w ago
Stable — net -4 jobs in 30d
6 added, 10 removed. Backfill posture.
Attractive for commercial and regulatory talent betting on rare obesity upside, but R&D-heavy cash burn and shallow pipeline pose medium-term sustainability risk.
Help build intelligence for Rhythm Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rhythm Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FDA-approved MC4 agonist driving company revenue and commercial hiring surge; only approved therapy for multiple genetic obesity forms.
Rhythm Pharmaceuticals Gains on European Approval for Obesity Drug - Investing.com
Rhythm Pharmaceuticals Gains on European Approval for Obesity Drug Investing.com
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 Stock Titan
Biotech veteran Kim Popovits joins Rhythm board as Ed Mathers leaves - Stock Titan
Biotech veteran Kim Popovits joins Rhythm board as Ed Mathers leaves Stock Titan
Rhythm Pharmaceuticals: Imcivree FDA Approval & Market Growth in 2025 - News and Statistics - IndexBox
Rhythm Pharmaceuticals: Imcivree FDA Approval & Market Growth in 2025 - News and Statistics IndexBox
Rhythm Pharmaceuticals’ Stock Jumps After New Drug Approval - timothysykes.com
Rhythm Pharmaceuticals’ Stock Jumps After New Drug Approval timothysykes.com
Is This Weight Loss Drug Stock a Buy After a New Approval? - The Motley Fool
Is This Weight Loss Drug Stock a Buy After a New Approval? The Motley Fool
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Epidemiology of acquired hypothalamic obesity following traumatic brain injury and nonspecific hypothalamic microinjury: A nationwide German claims data analysis.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo